Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress – Yahoo Finance

NEWTON, Mass., October 06, 2021–(BUSINESS WIRE)–Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held virtually October 19-23, 2021.
Poster Details
Poster Title: Depletion of Large Granular Lymphocytes in A First-in-Human Clinical Trial of ABC008
Presenter: Steven A. Greenberg, M.D.
Date and Time: ePosters will be available for viewing on a virtual platform starting on Tuesday, October 19th and accessible via an online archive for one year following the Congress. ePosters will have no specific presentation date and time.
Abstract ID: PO-32
About ABC008
ABC008 is an anti-KLRG1 antibody capable of selectively depleting subpopulations of highly cytotoxic, tissue-damaging, late-differentiated effector memory (TEM) and effector (TEMRA) T cells while sparing regulatory T cells and central memory T cells. The flagship indication for ABC008 is inclusion body myositis (IBM), an autoimmune disease in which highly differentiated cytotoxic T cells that express KLRG1 attack muscle tissue. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABC008 for the treatment of IBM.
About Inclusion Body Myositis
IBM is the most prevalent acquired myopathy in adults older than age fifty, impacting approximately 20,000 patients in the United States with an estimated prevalence in the US of 71 cases per million adults. The disease becomes apparent during adulthood and is characterized by progressive weakness and atrophy of the muscles especially those of the arms and the legs. IBM can progress to cause severe disability. Muscle tissue from patients with IBM show the presence of highly differentiated cytotoxic T cells that express KLRG1.
About Abcuro
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise depletion of highly cytotoxic T cells. The company’s lead program is ABC008 for inclusion body myositis (IBM). Additional programs focus on the development of ABC008 for other diseases and the development of ABC015 for selective activation of T and NK cells in cancer. For more information, visit abcuro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005096/en/
Contacts
Christine Quern
CBQ Communications
[email protected]
617.650.8497
The company applied in April for Food and Drug Administration approval to sell the new product. Now that process could take a bit more time.
Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.
These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
Coronavirus cases are receding nationwide—but not in every state. In fact, in some states in America, cases are actually rising quickly, as the virus lowers in former hotspots in the South. Where is COVID rising and how can you stay safe no matter where you live? Read on for the 5 states that have the fastest rising caseloads—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Vermont "Despite having the highest vaccination rates in the cou
Is Pfizer stock a buy after the CDC recommended Covid booster shots for people age 65 and older, and otherwise vulnerable Americans?
Are you looking for biotech stocks that could shoot higher? Wall Street analysts who cover the stocks on this list think they could provide some eye-popping gains. Every stock on this list has a consensus price target that's 91% above its present price.
One of the world’s largest and most important industries is ripe for disruption, and an under-the-radar artificial intelligence firm is ready to try its luck
As coronavirus cases, deaths and hospitalizations decline nationwide, Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allergy and Infectious Diseases, is happy to see it—but also realistic about the chances of another surge. Whether or not we have one depends on a few factors, which he outlined this morning on Fox News Sunday with host Chris Wallace. Read on for five life-saving predictions and pieces of advice—and to ensure your health
Over the past 10 years, U.S. stocks have delivered outstanding returns for investors. The major stock indices such as the Dow Jones Industrial Average, the NASDAQ Composite, and the S&P 500 have all climbed by more than 200% during this boom period. For example, biotech innovators Axsome Therapeutics (NASDAQ: AXSM) and Moderna (NASDAQ: MRNA), along with electric-car giant Tesla (NASDAQ: TSLA), have all generated well over 1,000% returns on capital for investors in just the past three years.
Online retailer ASOS was widely praised for introducing a menopause leave policy.
The idea is to offer additional flexibility so that Americans in certain situations can receive booster doses of a different vaccine than they received for their initial dose.
HCA Healthcare Inc. today opened its new $9.7 million, 11,000-square-foot ChampionsGate Emergency, a freestanding emergency department in Polk County. It provides 24/7 emergency care in the ChampionsGate and Four Corners area of Orlando and features 11 private patient care rooms and a cardiopulmonary resuscitation room, laboratory and imaging services, including a CT scanner, ultrasound and X-ray. Bradenton-based The PHM Group Inc. was the general contractor for the project.
Powell's death reminds us that COVID-19 is not just a pandemic of the unvaccinated, but of the elderly, too.
More COVID-19 booster shots may be on the way — but when it’s your turn, you’ll get an extra dose of the original vaccine, not one updated to better match the extra-contagious delta variant. “Don’t we want to match the new strains that are most likely to circulate as closely as possible?” Dr. Cody Meissner of Tufts Medical Center, an adviser to the Food and Drug Administration, challenged Pfizer scientists recently. “I don't quite understand why this is not delta because that's what we're facing right now,” fellow adviser Dr. Patrick Moore of the University of Pittsburgh said last week as government experts debated whether it's time for Moderna boosters.
"My goal is to get hopefully 80% or 90% to where I was," Robby Walker told CNN
Expert panel of patient advocacy leaders on COVID-19, its impact on patients and moving forward
Even as the pandemic appears to be receding, a culture war over vaccine mandates is showing signs of only growing more intense.
Photo Illustration by The Daily Beast / Photos GettyWhen the death of Colin Powell due to complications from COVID-19 was announced early Monday, medical experts feared that anti-vaxxers and others who question the reality of safe and effective shots might try to use the tragedy to fuel their conspiracy-laden agenda.It didn’t take long for those worries to come to fruition.In a statement, Powell’s family said the beloved 84-year-old general and former official in multiple Republican administrati

source